Levetiracetam Tablet
Product Images NDC 69102-106

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 69102-106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Owp Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000 mg (120)

Label for Roweepra levetiracetam tablets USP 1000 mg, an oral tablet dosage form. The label states a package quantity of 120 tablets and includes cautionary dispensing instructions. Manufactured for OWP Pharmaceuticals, Inc. with product NDC 69102-107-01, the label also features a barcode and manufacturing information from Torrent Pharmaceuticals Ltd.*

FDA Label Image

1000 mg (60)

Roweepra 1000 mg tablets USP packaging label for levetiracetam oral tablets, showing the brand name, dosage strength, and quantity of 60 tablets. Label includes caution to verify product dispensed, manufacturer information for OWP Pharmaceuticals, Inc., and Torrent Pharmaceuticals Ltd. The label also displays an NDC barcode and states Rx only.*

FDA Label Image

250 mg (Roweepra 250mg)

The image shows a packaging label for Roweepra (levetiracetam tablets USP) with a strength of 250 mg per tablet. The label indicates 120 tablets in the package and includes manufacturer information for OWP Pharmaceuticals, Inc. and Torrent Pharmaceuticals Ltd. The label features the NDC number 69102-108-01 and includes usage cautions and storage instructions.*

FDA Label Image

500 mg (Roweepra 500mg)

Label for Roweepra 500 mg oral tablets containing levetiracetam USP, manufactured by OWP Pharmaceuticals, Inc. The label displays the product name, strength (500 mg), quantity (120 tablets), and storage instructions. It includes cautionary text to verify the product dispensed and dispense the Medication Guide to each patient. The label shows the NDC number 69102-105-01 and identifies the manufacturer location in Naperville, IL, along with the repackager information in India.*

FDA Label Image

750 mg (Roweepra 750mg)

Label for Roweepra (levetiracetam tablets USP) 750 mg oral tablets, with a count of 120 tablets. The label includes dosage strength in a highlighted box and caution information to verify product dispensed and to provide the medication guide. It is manufactured for OWP Pharmaceuticals, Inc., and indicates Rx only status.*

FDA Label Image

Image (Torrent)

FDA Label Image

Fig 1 (Fig 1)

A bar graph showing the percentage of patients in three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis represents the percentage of patients, with values approximately 7.4% for Placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day. Sample sizes are included for each group.*

FDA Label Image

Fig 2 (Fig 2)

A bar graph showing the percentage of patients in three groups: placebo (6.3%, N=111), levetiracetam 1000 mg/day (20.8%, N=106), and levetiracetam 2000 mg/day (35.2%, N=105). The graph indicates higher patient percentages with increasing levetiracetam dosage.*

FDA Label Image

Fig 3 (Fig 3)

A bar chart comparing the percentage of patients between two groups: placebo (14.4%) and Levetiracetam 3000 mg/day (39.4%). The x-axis labels the groups with patient counts (N=104 for placebo, N=180 for Levetiracetam), and the y-axis shows the percentage of patients from 0% to 45%.*

FDA Label Image

Fig 4 (Fig 4)

A bar graph comparing the percentage of patients in two groups: Placebo (N=97) at 19.6% and Levetiracetam (N=101) at 44.6%. The vertical axis represents the percentage of patients. An asterisk indicates statistical significance or emphasis above the Levetiracetam bar.*

FDA Label Image

Fig 5 (Fig 5)

A bar chart comparing the percentage of patients between two groups: Placebo (N=51) and Levetiracetam (N=58). The chart shows approximately 19.6% for the Placebo group and 43.1% for the Levetiracetam group, with the Levetiracetam bar marked with an asterisk.*

FDA Label Image

Fig 6 (Fig 6)

Bar chart comparing the percentage of patients between placebo (N=84) and Levetiracetam (N=79). The placebo group shows 45.2% patients, while the Levetiracetam group shows 72.2% patients, with an asterisk indicating statistical significance.*

FDA Label Image

Str (Str)

Chemical structure diagram of levetiracetam, illustrating its molecular framework with atoms and bonds, including a pyrrolidone ring and various functional groups consistent with its chemical identity.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.